A Phase 1/2 interventional study of GX-188E and KEYTRUDA® in Cervical Cancer, sponsored by Genexine, Inc.. Completed at 9 sites in South Korea. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-30.
Sponsored by Genexine, Inc. · Phase 1/2, Interventional, and Treatment
A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer
This is an open-label Phase Ib-II trial to evaluate the safety and efficacy of GX-188E (IM administration using Ichor TDS-IM device) + pembrolizumab (P) in patients with advanced HPV-16+ or HPV-18+ cervical cancer.
2,366 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.
This study's enrollment of 65 is below the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.
Browse Uterine Cervical Neoplasms studies →Genexine, Inc. is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg KEYTRUDA® : Day 1 q3 weeks/ 200mg
Drug: GX-188E · Drug: KEYTRUDA®
DLT Evaluation for Safety and Tolerability(Part A)
Patient will be evaluated for the first 21 days for dose-limiting toxicities.
Time frame: within 21days
ORR for Efficacy (Part B&C)
ORR within 24 weeks (ORR24) evaluated by RECIST v1.1
Time frame: within 24 weeks
ORR for Efficacy (Part A)
Overall Response Rate within 24 weeks (ORR24) by RECIST v1.1 and immune-related Response Criteria (irRC)
Time frame: within 24 weeks
BORR (Part B&C)
Best Overall Response Rate(BORR) by RECIST v1.1
Time frame: up to 1 year
Time-to-Best Response
Time-to-Best Response by RECIST v1.1 and iRECIST
Time frame: up to 1 year
Duration of Response (DOR)
Duration of Response (DOR) by RECIST v1.1 and iRECIST
Time frame: up to 1 year
Progression-Free Survival (PFS)
6month- PFS by RECIST v1.1 and iRECIST
Time frame: up to 6 months
Overall Survival (OS)
Overall Survival (OS) by RECIST v1.1 and iRECIST
Time frame: up to 1 year
A total of 90 subjects were enrolled, of which 25 subjects were considered as screen failures. Of 90 Screened, 65 met Inclusion/Exclusion Criteria and were Randomized to treatment.
| Milestone | Single Arm (GX-188E + Pembrolizumab) |
|---|---|
| Started | 6 |
| Completed | 2 |
| Not completed | 4 |
| Withdrew: Disease relapse or progression | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 1 |
| Milestone | Single Arm (GX-188E + Pembrolizumab) |
|---|---|
| Started | 31 |
| Completed | 8 |
| Not completed | 23 |
| Withdrew: Disease relapse or progression | 18 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Adverse event | 2 |
| Withdrew: Physician decision | 1 |
| Milestone | Single Arm (GX-188E + Pembrolizumab) |
|---|---|
| Started | 65 |
| Completed | 12 |
| Not completed | 53 |
| Withdrew: Disease relapse or progression | 43 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Physician decision | 2 |
| Withdrew: Death | 1 |
Patient will be evaluated for the first 21 days for dose-limiting toxicities.
| participants | GX-188E, KEYTRUDA® |
|---|---|
| DLT Evaluation for Safety and Tolerability(Part A) | 0 |
ORR within 24 weeks (ORR24) evaluated by RECIST v1.1
| percentage of responders | GX-188E, KEYTRUDA® |
|---|---|
| Part B | 41.4 (25.89 to 100.00) |
| Part C | 35.0 (22.93 to 47.07) |
Overall Response Rate within 24 weeks (ORR24) by RECIST v1.1 and immune-related Response Criteria (irRC)
| percentage of responders | GX-188E, KEYTRUDA® |
|---|---|
| ORR for Efficacy (Part A) | 50.0 (11.81 to 88.19) |
Best Overall Response Rate(BORR) by RECIST v1.1
| percentage of responders | GX-188E, KEYTRUDA® |
|---|---|
| Part A | 50.0 (11.81 to 88.19) |
| Part B | 41.4 (23.52 to 61.06) |
| Part C | 35.0 (22.93 to 47.07) |
Time-to-Best Response by RECIST v1.1 and iRECIST
| Months | GX-188E, KEYTRUDA® |
|---|---|
| Part A | 2.07 (2.07 to NA) |
| Part B | 2.10 (2.04 to 4.01) |
| Part C | 2.10 (2.07 to 3.02) |
Duration of Response (DOR) by RECIST v1.1 and iRECIST
| Months | GX-188E, KEYTRUDA® |
|---|---|
| Part A | NA (2.40 to NA) |
| Part B | 5.78 (2.40 to NA) |
| Part C | NA (5.32 to NA) |
6month- PFS by RECIST v1.1 and iRECIST
| Months | GX-188E, KEYTRUDA® |
|---|---|
| Part A | 4.25 (2.04 to NA) |
| Part B | 4.14 (2.07 to 8.38) |
| Part C | 4.40 (2.14 to 8.31) |
Overall Survival (OS) by RECIST v1.1 and iRECIST
| Months | GX-188E, KEYTRUDA® |
|---|---|
| Part A | 15.54 (3.48 to NA) |
| Part B | 14.42 (8.97 to NA) |
| Part C | 23.79 (14.03 to NA) |
Collected over 24 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GX-188E, KEYTRUDA® | 31/65 (47.7%) | 25/65 (38.5%) | 54/65 (83.1%) |
| Event | GX-188E, KEYTRUDA® |
|---|---|
| Urinary tract infectionInfections and infestations | 7/65 |
| PyrexiaGeneral disorders | 3/65 |
| PneumoniaInfections and infestations | 2/65 |
| AstheniaGeneral disorders | 2/65 |
| AppendicitisInfections and infestations | 1/65 |
| GastroenteritisInfections and infestations | 1/65 |
| Kidney infectionInfections and infestations | 1/65 |
| LymphangitisInfections and infestations | 1/65 |
| Ophthalmic herpes zosterInfections and infestations | 1/65 |
| PeritonitisInvestigations | 1/65 |
| Event | GX-188E, KEYTRUDA® |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 19/65 |
| HypothyroidismEndocrine disorders | 10/65 |
| Blood creatinine increasedInvestigations | 8/65 |
| PyrexiaGeneral disorders | 8/65 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/65 |
| ConstipationGastrointestinal disorders | 7/65 |
| DiarrhoeaGastrointestinal disorders | 7/65 |
| Abdominal painGastrointestinal disorders | 6/65 |
| NauseaGastrointestinal disorders | 6/65 |
| VomitingGastrointestinal disorders | 6/65 |
| Age, Categorical(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| Part A — <=18 years | 0 |
| Part A — Between 18 and 65 years | 5 |
| Part A — >=65 years | 1 |
| Part B — <=18 years | 0 |
| Part B — Between 18 and 65 years | 29 |
| Part B — >=65 years | 2 |
| Part C — <=18 years | 0 |
| Part C — Between 18 and 65 years | 59 |
| Part C — >=65 years | 6 |
| Sex: Female, Male(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| Female | 65 |
| Male | 0 |
| Race (NIH/OMB)(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 65 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| PD-L1 expression status(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| Part A — Positive (≥1 CPS) | 0 |
| Part A — Negative (<1 CPS) | 6 |
| Part B — Positive (≥1 CPS) | 15 |
| Part B — Negative (<1 CPS) | 16 |
| Part C — Positive (≥1 CPS) | 39 |
| Part C — Negative (<1 CPS) | 26 |
| Histologic Type(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| Part A — Squamous Cell Carcinoma | 3 |
| Part A — Adenocarcinoma | 3 |
| Part B — Squamous Cell Carcinoma | 23 |
| Part B — Adenocarcinoma | 8 |
| Part C — Squamous Cell Carcinoma | 50 |
| Part C — Adenocarcinoma | 15 |
| HPV type(Participants) | GX-188E, KEYTRUDA® |
|---|---|
| Part A — HPV-16 | 3 |
| Part A — HPV-18 or both | 3 |
| Part B — HPV-16 | 24 |
| Part B — HPV-18 or both | 7 |
| Part C — HPV-16 | 49 |
| Part C — HPV-18 or both | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HPV E6/E7 DNA Vaccine GX-188E